San Diego-based mostly Viking Therapeutics marked itself as a serious competitor inside the weight loss drug industry in February following revealing promising data from a mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in March the